drugset
drugset / Trial / NCT04164199

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

NCT04164199 ↗

Phase 3 Completed 404 enrolled BeOne Medicines
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).

Timeline

Start
2019-12-19
Primary completion
2026-05-23
Completion
2026-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcestobart Monoclonal antibody — Intravenous
Subject BAT1706 Unknown — Intravenous
Subject BGB-15025 Unknown — Oral
Subject Fruquintinib Small molecule — Oral
Subject Gimistotug Monoclonal antibody — Intravenous
Subject Lenvatinib Small molecule — Oral
Subject Ociperlimab Monoclonal antibody — Intravenous
Subject Pamiparib Small molecule — Oral
Subject Sitravatinib Small molecule — Oral
Subject Surzebiclimab Monoclonal antibody — Intravenous
Subject Temozolomide Small molecule — Oral
Subject Tislelizumab Monoclonal antibody — Intravenous
Subject Zanidatamab Monoclonal antibody — Intravenous

Indications

cancer